The Asia Pacific Research-grade Proteins Market would witness market growth of 16.1% CAGR during the forecast period (2023-2030).
The increasing preference for recombinant proteins over natural proteins in scientific research results from the benefits offered by these proteins. Recombinant proteins, for instance, can be synthesized with a high protein yield, no animal contaminants, and batch-to-batch variation under control. For research applications, recombinant proteins from the growth factor family, such as fibroblast growth factors, vascular endothelial growth factors, and neurotrophins, are frequently used. Increasing use of recombinant proteins in research activities is expected to accelerate the growth of the market over the forecast period.
Sophisticated research and knowledge of drug-targeting mechanisms is essential for drug development. Numerous regions have created biobanks from cohort programs to provide researchers with high-quality samples for redefining treatment strategies. This is expected to culminate in a greater emphasis on biomarker discovery for various diseases. Thus, initiatives and government interest in research activities for better healthcare infrastructure will continue to increase the applications of research-grade proteins, thereby propelling market expansion.
The APAC region is home to numerous prestigious academic and research institutions conducting cutting-edge research in genomics, proteomics, molecular biology, and disease biology. These institutions drive the demand for research-grade proteins. APAC countries, including China, India, South Korea, and Singapore, have grown significantly in their biotechnology and pharmaceutical sectors. These industries heavily rely on these proteins for drug discovery, development, and clinical research. APAC has become a hub for biopharmaceutical manufacturing, with many companies producing biologics, monoclonal antibodies, and biosimilars.
The China region dominated the Asia Pacific Research-grade Proteins Market, by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $171.8 Million by 2030. The Japan market is registering a CAGR of 15.3% during (2023 - 2030). Additionally, The India market would showcase a CAGR of 16.7% during (2023 - 2030).
Based on Host Cell, the market is segmented into Mammalian Cells, Bacterial Cells, Yeast & Fungi, Insect Cells, and Others. Based on Product, the market is segmented into Cytokines & Growth Factors, Immune Checkpoint Proteins, Enzymes, Hormones, Antibodies, Virus Antigens, Recombinant Regulatory Proteins, and Others. Based on End-use, the market is segmented into Pharmaceutical & Biotechnology Companies, Academic & Research Institutes, and Others. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Thermo Fisher Scientific, Inc., Abcam Plc, Miltenyi Biotech B.V. & Co. KG, Genscript Biotech Corporation, Bio-Techne Corporation, Proteintech Group, Inc., AcroBiosystems INC., Sino Biologicals, Inc. and ProSpec-Tany TechnoGene Ltd. and New England Biolabs, Inc.
The increasing preference for recombinant proteins over natural proteins in scientific research results from the benefits offered by these proteins. Recombinant proteins, for instance, can be synthesized with a high protein yield, no animal contaminants, and batch-to-batch variation under control. For research applications, recombinant proteins from the growth factor family, such as fibroblast growth factors, vascular endothelial growth factors, and neurotrophins, are frequently used. Increasing use of recombinant proteins in research activities is expected to accelerate the growth of the market over the forecast period.
Sophisticated research and knowledge of drug-targeting mechanisms is essential for drug development. Numerous regions have created biobanks from cohort programs to provide researchers with high-quality samples for redefining treatment strategies. This is expected to culminate in a greater emphasis on biomarker discovery for various diseases. Thus, initiatives and government interest in research activities for better healthcare infrastructure will continue to increase the applications of research-grade proteins, thereby propelling market expansion.
The APAC region is home to numerous prestigious academic and research institutions conducting cutting-edge research in genomics, proteomics, molecular biology, and disease biology. These institutions drive the demand for research-grade proteins. APAC countries, including China, India, South Korea, and Singapore, have grown significantly in their biotechnology and pharmaceutical sectors. These industries heavily rely on these proteins for drug discovery, development, and clinical research. APAC has become a hub for biopharmaceutical manufacturing, with many companies producing biologics, monoclonal antibodies, and biosimilars.
The China region dominated the Asia Pacific Research-grade Proteins Market, by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $171.8 Million by 2030. The Japan market is registering a CAGR of 15.3% during (2023 - 2030). Additionally, The India market would showcase a CAGR of 16.7% during (2023 - 2030).
Based on Host Cell, the market is segmented into Mammalian Cells, Bacterial Cells, Yeast & Fungi, Insect Cells, and Others. Based on Product, the market is segmented into Cytokines & Growth Factors, Immune Checkpoint Proteins, Enzymes, Hormones, Antibodies, Virus Antigens, Recombinant Regulatory Proteins, and Others. Based on End-use, the market is segmented into Pharmaceutical & Biotechnology Companies, Academic & Research Institutes, and Others. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Thermo Fisher Scientific, Inc., Abcam Plc, Miltenyi Biotech B.V. & Co. KG, Genscript Biotech Corporation, Bio-Techne Corporation, Proteintech Group, Inc., AcroBiosystems INC., Sino Biologicals, Inc. and ProSpec-Tany TechnoGene Ltd. and New England Biolabs, Inc.
Scope of the Study
Market Segments Covered in the Report:
By Host Cell- Mammalian Cells
- Bacterial Cells
- Yeast & Fungi
- Insect Cells
- Others
- Cytokines & Growth Factors
- Immune Checkpoint Proteins
- Enzymes
- Hormones
- Antibodies
- Virus Antigens
- Recombinant Regulatory Proteins
- Others
- Pharmaceutical & Biotechnology Companies
- Academic & Research Institutes
- Others
- China
- Japan
- India
- South Korea
- Singapore
- Malaysia
- Rest of Asia Pacific
Key Market Players
List of Companies Profiled in the Report:
- Thermo Fisher Scientific, Inc.
- Abcam Plc
- Miltenyi Biotech B.V. & Co. KG
- Genscript Biotech Corporation
- Bio-Techne Corporation
- Proteintech Group, Inc.
- AcroBiosystems INC.
- Sino Biologicals, Inc.
- ProSpec-Tany TechnoGene Ltd.
- New England Biolabs, Inc.
Unique Offerings
- Exhaustive coverage
- The highest number of Market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market at a Glance
Chapter 3. Market Overview
Chapter 5. Asia Pacific Research-grade Proteins Market, by Host Cell
Chapter 6. Asia Pacific Research-grade Proteins Market, by Product
Chapter 7. Asia Pacific Research-grade Proteins Market, by End-use
Chapter 8. Asia Pacific Research-grade Proteins Market, by Country
Chapter 9. Company Profiles
Companies Mentioned
- Thermo Fisher Scientific, Inc.
- Abcam Plc
- Miltenyi Biotech B.V. & Co. KG
- Genscript Biotech Corporation
- Bio-Techne Corporation
- Proteintech Group, Inc.
- AcroBiosystems INC.
- Sino Biologicals, Inc.
- ProSpec-Tany TechnoGene Ltd.
- New England Biolabs, Inc.
Methodology
LOADING...
